Full-Time

Sales Operations Manager

Confirmed live in the last 24 hours

Calyxo

Calyxo

51-200 employees

Develops medical devices for kidney stone treatment

Compensation Overview

$122k - $135k/yr

+ Stock Options

Senior, Expert

No H1B Sponsorship

Remote in USA

Category
Sales Development Representative
Sales & Account Management
Required Skills
Tableau
Salesforce
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • B.A. in Business Management, Marketing, Finance, Computer Science or Similar Programs
  • 8+ years of strong analytical and problem-solving experience working in sales operations, business analyst role, process improvement, and/or program/project management, preferably at a medical device or life science company.
  • Intermediate to above average skills with Tableau
  • Intermediate level skills with Excel and PowerPoint
  • Data-driven problem solver with the ability to approach challenges or issues from multiple perspectives
  • Experience in providing meaningful narratives through the use of data and visualizations
  • Ability to quickly and effectively analyze data, extract trends from analysis, and translate trends into actionable and understandable insights (applicant will be asked to present a past work of their own visual analytics during the interview process)
  • Strong leadership skills, with experience coaching direct/indirect reports to drive high performing team
  • Demonstrated organizational skills, attentiveness to detail, ability to work under limited supervision, and the ability to handle multiple projects simultaneously
  • Excellent verbal and written communication skills
  • Ability to occasionally travel as needed
Responsibilities
  • Develop and distribute commercial analytics reports and dashboards in Salesforce and Tableau to provide actionable insights that support data-driven decision-making for the commercial and executive leadership teams.
  • Monitor data integrity in Salesforce and Tableau with thorough review and audit of systems, including coordinating with appropriate teams on resolution and next steps.
  • Lead quarterly/annual territory planning for respective areas, including recommending new territory locations based on market modeling. Tracking zip code alignment changes and updating AcuityMD, Salesforce and Tableau accordingly.
  • Help with salesforce quota modeling and administration
  • Proactively gather user enhancement requests and analyze requirements, tradeoffs, priorities, and solutions to make recommendations to functional leaders.
  • Respond to ad hoc requests for insights, delivering material in a succinct and effective manner to fulfill communication needs with internal and external stakeholders with a high degree of accuracy, appropriate context on data and insights / narratives as needed
  • Partner closely with senior leadership to solicit feedback and present recommendations around performance metrics, goals and scorecards
  • Apply quantitative analysis and data visualization to tell the story behind the numbers.
  • Partner with our commercial team to identify process bottlenecks and provide recommendations and solutions to track and improve the commercial team’s performance.
  • Engage in frequent interaction with the commercial leadership, reimbursement and finance teams to assist with questions, process improvements, and complex sales flows and data analysis.
  • Establish best practices in terms of processes for data governance to improve data quality and transparency
  • Establish operational processes that ensure data accuracy and freshness
  • Self-direct and prioritize incoming requests for analysis projects.

Calyxo develops medical devices specifically designed to treat kidney stones. Their products focus on improving the effectiveness and safety of treatment options available to urologists. By collaborating with leading urologists, Calyxo ensures that their devices meet the real clinical needs of healthcare providers. Unlike many competitors, Calyxo emphasizes a strong partnership with medical professionals to enhance patient care and clinical outcomes. The company's goal is to provide advanced solutions that enable urologists to treat kidney stones more efficiently, ultimately improving the overall experience for patients.

Company Size

51-200

Company Stage

Series D

Total Funding

$97.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance for the redesigned CVAC System boosts market credibility and adoption.
  • Rising prevalence of kidney stones expands Calyxo's potential customer base.
  • Series D funding of $50M supports further innovation and market expansion.

What critics are saying

  • Emerging competition may impact Calyxo's market share in kidney stone treatments.
  • Economic downturns could reduce healthcare spending on new medical devices.
  • Rapid technological advancements require Calyxo to continuously innovate to stay competitive.

What makes Calyxo unique

  • Calyxo's CVAC System offers superior stone clearance compared to standard URS.
  • The company focuses on minimally invasive kidney stone treatments with high patient satisfaction.
  • Calyxo collaborates with leading urologists to enhance R&D and device innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-7%
Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

Finsmes
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

Business Wire
Jul 6th, 2022
Calyxo Raises $32.7 Million In Series C Financing To Support Novel Approach To Treating Kidney Stones

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo has developed the innovative CVAC Aspiration System that utilizes irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome, a challenge that has always been difficult to achieve consistently